Zika Virus Therapeutics Market Report 2026

The zika virus therapeutics market size has grown strongly in recent years. It will grow from $32.06 billion in 2025 to $34 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to historical outbreaks in endemic regions, reliance on symptomatic treatment approaches, expansion of public health monitoring systems, development of basic diagnostic tools, increased awareness of congenital zika complications.

The zika virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $42.49 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing investments in infectious disease research, rising demand for preventive vaccines, expansion of global disease surveillance networks, growing focus on maternal health protection, increasing collaboration between public health agencies. Major trends in the forecast period include increasing focus on antiviral drug development, growing investment in vaccine research programs, expansion of supportive care therapeutics, rising surveillance of vector-borne diseases, improved public health preparedness.

The high incidence of infection is expected to propel the growth of the Zika virus therapeutics market going forward. Infection rate refers to the probability or risk of an infection occurring within a specific population over a defined time period. The rise in infection incidence is driven by factors such as insufficient vector control, environmental conditions that favor mosquito breeding, and limited access to preventive healthcare in affected regions. Higher infection rates increase the demand for effective Zika virus therapeutics, encouraging the development and investment in vaccines and treatments to address this growing public health concern. For instance, in December 2024, according to the UK Health Security Agency, a UK-based government organization, approximately eight confirmed cases of the Zika virus were reported between January and June 2024, representing a 700% increase in incidence compared with the same period in 2023. Therefore, the increasing incidence of infection is driving the growth of the Zika virus therapeutics market.

Key companies in the Zika virus therapeutics market are focusing on innovative technologies, such as second-generation adjuvanted inactivated vaccines, to enhance immune response, improve vaccine efficacy, and provide longer-lasting protection against the virus. A second-generation adjuvanted inactivated vaccine combines an inactivated virus with an immune-boosting adjuvant to strengthen the body’s immune response for more effective protection against the disease. For instance, in March 2024, Valneva SE, a France-based biotechnology company specializing in vaccines, initiated Phase 1 clinical trials for VLA1601, a highly purified inactivated vaccine candidate against Zika virus (ZIKV). VLA1601 was developed using the same manufacturing platform as Valneva’s licensed Japanese encephalitis vaccine, IXIARO, and includes adjuvants to enhance the immune response, which is critical for vaccine effectiveness.

In September 2024, Indian Immunologicals, an India-based vaccine manufacturer, partnered with the Indian Council of Medical Research to emphasize the development of safe and cost-effective vaccines for emerging viral diseases, particularly Zika, which poses significant health risks, especially to pregnant women. The Indian Council of Medical Research is India’s apex biomedical research body.

Major companies operating in the zika virus therapeutics market are Johnson & Johnson, Merck & Co Inc, Sanofi S A, Takeda Pharmaceutical Company Limited, Moderna Inc, Emergent BioSolutions Inc, Valneva SE, Bharat Biotech International Limited, Inovio Pharmaceuticals Inc, GeoVax Labs Inc, GlaxoSmithKline plc, Novavax Inc, Pfizer Inc, GeneOne Life Science Inc, Zydus Cadila, Indian Immunologicals Limited, Enesi Pharma, Protein Sciences Corporation, Sementis Ltd, Hawaii Biotech Inc, GeneOne Life Science.

North America was the largest region in the zika virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zika virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zika virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the zika virus therapeutics market by increasing costs of imported diagnostic kits, laboratory reagents, vaccine development materials, and pharmaceutical manufacturing inputs. Public health agencies and healthcare providers in North America and Latin America are most affected due to reliance on imported medical supplies, while Asia-Pacific faces cost pressure on vaccine research components. These tariffs are raising development and procurement costs and slowing emergency response readiness. However, they are also encouraging regional manufacturing of diagnostics and therapeutics, strengthening local public health infrastructure.

The zika virus therapeutics market research report is one of a series of new reports that provides zika virus therapeutics market statistics, including zika virus therapeutics industry global market size, regional shares, competitors with a zika virus therapeutics market share, detailed zika virus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the zika virus therapeutics industry. This zika virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zika virus therapeutics refer to medical treatments, drugs, or therapies specifically developed to prevent or manage Zika virus infection. The virus is primarily transmitted through mosquito bites and can cause symptoms such as fever, rash, and joint pain. Management of Zika virus infection is mainly supportive, focusing on symptom relief, hydration, and monitoring for severe complications, including congenital Zika syndrome in newborns.

The primary product types of Zika virus therapeutics are acetaminophen and other non-steroidal anti-inflammatory drugs (NSAIDs). Acetaminophen acts as a pain reliever and fever reducer, commonly used to alleviate mild to moderate pain and reduce fever. These therapeutics are further categorized by vaccine type, including inactivated vaccines, subunit vaccines, live-attenuated vaccines, and other vaccine types. They are utilized by end users such as hospitals, clinics, and other healthcare facilities.

The zika virus therapeutics market consists of sales of vaccines, antiviral drugs and antibody based therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.